Beckmann, K.; Reitinger, C.; Yan, X.; Carle, A.; Blümle, E.; Jurkschat, N.; Paulmann, C.; Prassl, S.; Kazandjian, L.V.; Loré, K.;
et al. Fcγ-Receptor-Independent Controlled Activation of CD40 Canonical Signaling by Novel Therapeutic Antibodies for Cancer Therapy. Antibodies 2024, 13, 31.
https://doi.org/10.3390/antib13020031
AMA Style
Beckmann K, Reitinger C, Yan X, Carle A, Blümle E, Jurkschat N, Paulmann C, Prassl S, Kazandjian LV, Loré K,
et al. Fcγ-Receptor-Independent Controlled Activation of CD40 Canonical Signaling by Novel Therapeutic Antibodies for Cancer Therapy. Antibodies. 2024; 13(2):31.
https://doi.org/10.3390/antib13020031
Chicago/Turabian Style
Beckmann, Karsten, Carmen Reitinger, Xianglei Yan, Anna Carle, Eva Blümle, Nicole Jurkschat, Claudia Paulmann, Sandra Prassl, Linda V. Kazandjian, Karin Loré,
and et al. 2024. "Fcγ-Receptor-Independent Controlled Activation of CD40 Canonical Signaling by Novel Therapeutic Antibodies for Cancer Therapy" Antibodies 13, no. 2: 31.
https://doi.org/10.3390/antib13020031
APA Style
Beckmann, K., Reitinger, C., Yan, X., Carle, A., Blümle, E., Jurkschat, N., Paulmann, C., Prassl, S., Kazandjian, L. V., Loré, K., Nimmerjahn, F., & Fischer, S.
(2024). Fcγ-Receptor-Independent Controlled Activation of CD40 Canonical Signaling by Novel Therapeutic Antibodies for Cancer Therapy. Antibodies, 13(2), 31.
https://doi.org/10.3390/antib13020031
